CN1102931C - 具有免疫调解剂作用的酰化n－羟甲基酞胺哌啶酮－前药 - Google Patents

具有免疫调解剂作用的酰化n－羟甲基酞胺哌啶酮－前药 Download PDF

Info

Publication number
CN1102931C
CN1102931C CN97193682A CN97193682A CN1102931C CN 1102931 C CN1102931 C CN 1102931C CN 97193682 A CN97193682 A CN 97193682A CN 97193682 A CN97193682 A CN 97193682A CN 1102931 C CN1102931 C CN 1102931C
Authority
CN
China
Prior art keywords
neurosedyn
prodrug
expression
acid
thalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97193682A
Other languages
English (en)
Chinese (zh)
Other versions
CN1215397A (zh
Inventor
J·施纳特
W·温特
S·沃南特
K·兹温根伯格
K·艾格
M·艾克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grünenthal GmbH
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CN1215397A publication Critical patent/CN1215397A/zh
Application granted granted Critical
Publication of CN1102931C publication Critical patent/CN1102931C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
CN97193682A 1996-04-09 1997-03-22 具有免疫调解剂作用的酰化n－羟甲基酞胺哌啶酮－前药 Expired - Fee Related CN1102931C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19613976.7 1996-04-09
DE19613976A DE19613976C1 (de) 1996-04-09 1996-04-09 Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Publications (2)

Publication Number Publication Date
CN1215397A CN1215397A (zh) 1999-04-28
CN1102931C true CN1102931C (zh) 2003-03-12

Family

ID=7790778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97193682A Expired - Fee Related CN1102931C (zh) 1996-04-09 1997-03-22 具有免疫调解剂作用的酰化n－羟甲基酞胺哌啶酮－前药

Country Status (12)

Country Link
US (1) US6417197B1 (enExample)
EP (1) EP0892794B1 (enExample)
JP (1) JP2000508298A (enExample)
CN (1) CN1102931C (enExample)
AT (1) ATE212989T1 (enExample)
AU (1) AU707144B2 (enExample)
DE (2) DE19613976C1 (enExample)
DK (1) DK0892794T3 (enExample)
ES (1) ES2171923T3 (enExample)
HU (1) HUP9902181A3 (enExample)
PT (1) PT892794E (enExample)
WO (1) WO1997037988A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
AU752958B2 (en) * 1997-11-18 2002-10-03 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce TNFalpha levels
WO2001041755A2 (en) * 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) * 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
CN100488959C (zh) * 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) * 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
CN100398534C (zh) * 2003-09-15 2008-07-02 天津和美生物技术有限公司 合成酞胺哌啶酮及其衍生物的方法
CA2808646C (en) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1682126B1 (en) * 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2004614B1 (en) 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
CA2957226C (en) * 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
TWI782395B (zh) * 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018496A1 (de) * 1991-04-17 1992-10-29 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
US5385901A (en) * 1991-02-14 1995-01-31 The Rockefeller University Method of treating abnormal concentrations of TNF α

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385901A (en) * 1991-02-14 1995-01-31 The Rockefeller University Method of treating abnormal concentrations of TNF α
WO1992018496A1 (de) * 1991-04-17 1992-10-29 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln

Also Published As

Publication number Publication date
AU707144B2 (en) 1999-07-01
JP2000508298A (ja) 2000-07-04
EP0892794B1 (de) 2002-02-06
DK0892794T3 (da) 2002-04-15
WO1997037988A1 (de) 1997-10-16
HUP9902181A2 (hu) 2000-04-28
HK1017350A1 (en) 1999-11-19
ATE212989T1 (de) 2002-02-15
PT892794E (pt) 2002-07-31
CN1215397A (zh) 1999-04-28
EP0892794A1 (de) 1999-01-27
AU2505297A (en) 1997-10-29
HUP9902181A3 (en) 2002-11-28
ES2171923T3 (es) 2002-09-16
US6417197B1 (en) 2002-07-09
DE59706313D1 (de) 2002-03-21
DE19613976C1 (de) 1997-11-20

Similar Documents

Publication Publication Date Title
US6417197B1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
FR2677361A1 (fr) Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CS228119B2 (en) Production of n2-arylsulphonyl-l-argininamides
JPS6227079B2 (enExample)
JPH08508720A (ja) ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物
CN1148596A (zh) 新晶形无水7-([1α，5α，6α]-6-氨基-3-氮杂二环[3.1.0]己-3-基)-6-氟-1-(2，4-二氟苯基)-1，4-二氢-4-氧代-1，8-二氮杂萘-3-羧酸甲磺酸盐
US6500845B1 (en) Lactam derivatives as immunomodulating agents
AU1641592A (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
US20090170937A1 (en) Amino Acid Derivatives
US4228183A (en) Novel phenethylamine derivatives and processes for preparing same
CA2251060C (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
CN85107088A (zh) 肽取代的杂环免疫刺激剂的制备
RU2481341C2 (ru) Кристаллические модификации 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона
US20090036525A1 (en) Non-Natural Amino Acid Derivatives
CN1128989A (zh) N-取代的氮杂环羧酸及其酯
HK1019588A (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
CN1067987C (zh) 取代的吲哚衍生物
JPH0625276A (ja) アシルアミノ糖誘導体及びその製法
CN1212317C (zh) 新颖的酯或酰胺衍生物
CN1360593A (zh) 假单胞菌素n－酰基侧链类似物
MXPA98007998A (en) Acrylic prodrogas of n-hydroxymethyl talidomide with immunomodula activity
HK1017350B (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
CN1138753C (zh) 二甲基取代的环己二烯衍生物
CN1062552C (zh) 环己二烯衍生物、含有它们的药物及其制备方法与用途
EP0308319B1 (en) 4-piperidinecarboxamide derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1019588

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee